WVE Stock Overview
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Wave Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.77 |
| 52 Week High | US$7.67 |
| 52 Week Low | US$3.50 |
| Beta | -1.13 |
| 11 Month Change | -11.64% |
| 3 Month Change | -6.03% |
| 1 Year Change | 27.94% |
| 33 Year Change | -4.94% |
| 5 Year Change | -74.91% |
| Change since IPO | -63.94% |
Recent News & Updates
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25Recent updates
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Sep 24What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates
Aug 07Wave Life Sciences posts proof-of-concept data from genetic disorder study
Jun 02Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates
May 15Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade
Apr 02Shareholder Returns
| WVE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.0% | 2.1% | 0.1% |
| 1Y | 27.9% | 18.8% | 24.9% |
Return vs Industry: WVE exceeded the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: WVE exceeded the US Market which returned 25.9% over the past year.
Price Volatility
| WVE volatility | |
|---|---|
| WVE Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: WVE has not had significant price volatility in the past 3 months.
Volatility Over Time: WVE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 267 | Paul B. Bolno | www.wavelifesciences.com |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington’s disease (HD).
Wave Life Sciences Ltd. Fundamentals Summary
| WVE fundamental statistics | |
|---|---|
| Market cap | US$716.00m |
| Earnings (TTM) | -US$73.48m |
| Revenue (TTM) | US$110.50m |
6.5x
P/S Ratio-9.8x
P/E RatioIs WVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WVE income statement (TTM) | |
|---|---|
| Revenue | US$110.50m |
| Cost of Revenue | US$139.56m |
| Gross Profit | -US$29.06m |
| Other Expenses | US$44.43m |
| Earnings | -US$73.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | -26.30% |
| Net Profit Margin | -66.50% |
| Debt/Equity Ratio | 0% |
How did WVE perform over the long term?
See historical performance and comparison